

HIV

### In Labou

- Initiate ART d fixed-dose co
  - Tenofovir (T
  - Lamivudine
  - Efavirenz (E

- Continue ART with fixed-do TDF. 3TC and EFV once-da (see above)
- Perform WHO Clinical Stag and conduct the following laboratory testing
- CD4 count
- Full blood picture
- Renal and liver function tests

- with once daily fixed-dose combination:
- Tenofovir (TDF) 300 mg and
- Lamivudine (3TC) 300 mg
- Efavirenz (EFV) 600 mg

Women id HIV-positiv labo	ve during		
	r		I
bour and [	Delivery War	d	
<b>RT during la</b> <b>se combinati</b> vir (TDF) 300		e daily	
dine (3TC) 30	)0 mg and		
nz (EFV) 600	mg		
+	7		
After De ed-dose • e-daily	livery For CPT, refe in the guidelin of HIV.		
Staging • /ing	Schedule pos (7, 28 and 42 adequate sup	days) an	d ensure

• For RCH clinics that do not provide ART, refer to nearby CTC

# **Testing after Delivery**

- Perform WHO Clinical Staging and conduct the following laboratory testing
  - CD4 count
  - Full blood picture
  - Renal and liver function tests
- For CPT, refer to the adult criteria in the guidelines for management of HIV.





The United Republic of Tanzania **Ministry of Health** and Social Welfare

Age (weight)

**Birth-6 weeks (birth** 

weight <2500 gram)

NVP (Nevirapine) Syrup Dosing

**Once Dailv** 

Syrup 50 mg/5ml

10 mg = 1 ml

# **ARVs and cotimoxazole prophylaxis** in **PMTCT** Services **HIV-Exposed Infants**

### **Immediately after birth**

Ensure that all infants born to HIV-infected women receive ARV prophylaxis as soon as possible after birth:

### All HIV-exposed infants should receive NVP once daily from birth to six weeks of age

- Provide infant feeding information, counselling and support
- Emphasize breast feeding to 12 months of age and avoidance of mixed feeding in the first 6 months of life.
- If mother wants to formula feed, assess if AFASS and counsel accordingly. Discuss how mother will cope with possible stigmatisation if she chooses not to breastfeed and advise her on the suppression of lactation.
- **Administer immunisations**
- OPV-0 and BCG
- - nin A 50,000 IU

Birth–6 weeks ( weight ≥2500 gr	1 10 110 =	1.5 ml	<ul><li>Vitamin A</li><li>Formula-fed inf</li></ul>	ants only: administe		
Cotrimoxazole Preventive Therapy (CPT): Dosing Once Daily						
Recommended Daily Dosage	Suspension (5 ml syrup (200 mg/40 mg)	Paediatric tablet (100 mg/20 mg)	Single-strength adult tablet 400 mg/80 mg)	Double-strength adult tablet (100 mg/20 mg)		
<6 months	2.5ml	One tablet	¼ tablet, possibly mixed with feeding	One tablet		
6 months–5 years	5 ml	Two tablets	Two tablets	Two tablets		
>6–14 years	10 ml	Four tablets	Four tablets	Four tablets		
>14 years			_	_		

HIV Testing				
0–9 months	Use HIV viral testing (DNA-PCR)			
9–18 months	Use HIV antibody testing; re-test all positive results using HIV viral testing (DNA-PCR)			
≥18 months	Use HIV antibody testing			

# Monthly until HIV status determined

- Monitor growth and development
- Advise on infant ARV prophylaxis (breastfed infants whose mothers are NOT on ARV therapy, only):
- **Continue CPT: Adjust dose for** weight and continue until child is proven HIV-negative
- Provide infant feeding information, counselling and support
- Discuss complementary feeding starting from 6 months of age

- Administer Vitamin A:
- If symptomatic for HIV

- Administer immunisations

September 2013



 < 6 months: 50, 000 IU (formula fed infants only)</li> • At 9-12 months\*: 100,000 IU \*Timing should correspond with measles vaccination • At 15-18 months: 200,000 IU • At 21-24 months: 200,000 IU

Repeat HIV testing in infants who originally tested HIV-negative: At least 6 weeks after complete cessation of breast feeding • Use appropriate test for age

• 10 weeks: OPV 2, Pentavalent 2, PCV 2, Rotarix 2 • 14 weeks: OPV 3, Pentavalent 3, PCV 3 • 9 months: Measles — but only if no severe immunosuppression

